Details
Category: Volume 07 Issue 10 October 2019
Hits: 1069

Title: Study of Fasting and Postprandial Lipid Profiles in Type 2 Diabetes Mellitus

Authors: S.Pravin, R.Aswinth, S.Sudharsan

 DOI: https://dx.doi.org/10.18535/jmscr/v7i10.120

Abstract

   

Background and Objectives: Type 2 diabetes mellitus is associated with the development of premature atherosclerosis and a higher cardiovascular morbidity and mortality. Diabetic dyslipidemia is believed to play an important role in the pathogenesis of accelerated atherosclerosis in this condition. It is being increasingly believed that atherosclerosis is a postprandial phenomenon as at least with respect to lipids, we are in the postprandial phase for most of the day. High postprandial triglycerides have shown a strong and independent association with CAD. Hence this study is being carried out to assess the characteristics of postprandial dyslipidaemia in types 2 diabetes mellitus in comparison with the fasting lipid levels in diabetics and controls.

Methodology: This was an observational study which included the patients admitted in Raja Muthiah Medical College Hospital, Chidambaram, Tamilnadu .The study included 50 patients with type 2 diabetes mellitus meeting the inclusion criteria and were compared with 50 age and sex matched healthy controls, fulfilling the inclusion and exclusion criteria.

Method of Collection of Data: Data for the proposed study was collected in a pretested proforma. Detailed history and physical examination of all the cases and controls was done. Fasting and Post prandial lipid levels were estimated in all the cases and controls. Blood was collected from patients after an overnight (12-hour) fast and six hour postprandial (after a standard meal) for lipid profile measurements.

Results: The majority of cases were in the age group of 61-70 years. All the cases in the fasting state had a raised triglyceride (mean 172.92±75.51mg/dL) level, raised VLDL-C (mean 37.76±20.01mg/dL) level, decreased HDL-C (mean 33.44±11.99mg/dL) level, normal total cholesterol (mean176.36±52.43mg/dL) level and normal LDL-C  (mean 101.16±38.17mg/dL) levels compared to the control group. In the post prandial state the diabetics had a significant increase in the post prandial triglyceride level (mean 232.52±105.08mg/dL), decrease in the HDL-C level (mean 30.96±11.15mg/dL) compared to the fasting state whereas in the control group there was no significant increase in the post prandial lipid levels compared to the fasting state.

Conclusion: The dyslipidemia of Type 2 DM is characterised mainly of raised triglyceride levels, raised VLDL-C Levels and decreased HDL-C levels. In the post prandial state there was significant hyper-triglyceridaemia and decreased HDL-C level in diabetics when compared to that of the controls.

Keywords: Dyslipidemia, atherosclerosis, hyper-triglyceridaemia, postprandial dyslipidemia.

References

  1. Peter Mayes, Kathleen M. Botham. Lipids of physiologic significance. Robert K. Murray, Daryl K. Granner, Peter A. Mayes, Victor W Rodwell Editors. In Harper’s Illustrated Biochemistry: 26th Edition Mcgraw Hill, USA 121-132
  2. Robert W. Mahley, Karl Weisgraber, Thomas P. Bersot. Disorders of lipid metabolism. Henry M. Kronenberg, Shlomo Melmed, Kenneth S. Polonsky, Reed Larsen P Editors. In Williams Textbook of Endocrinology; 11th edition: Saunders Elsevier, Philadelphia, 1589- 1655.
  3. Barbara V Howard, James Howard Wm. Pathophysiology and treatment of lipiddisorders in diabete Ronald Kahn C, George L King Alan C Moses, Gordon C Weir, Alan M Jacobson, Robert J Smith Editors. In Joslin’s Diabetes mellitus: 14th edition: lippincott, philedelphia, 563-79.
  4. Hussain MM, Fatma S, Pan X, Iqbal J: Intestinal lipoprotein assembly. CurrOpin Lipidol 2005; 16:281-28
  5. Mahley RW, Huang Y, Rall Jr SC: Pathogenesis of type III hyper-lipoproteinemia (dysbetalipoproteinemia). questions, quandaries, and paradoxe J Lipid Res 2005; 16:281-285.
  6. Mahley RW, Rall Jr   SC:  Type III hyperlipoproteinemia (dysbetalipoproteinemia). The role of apolipoprotein E in normal and abnormal lipid metabolism. In: Scriver CR, Beaudet AL, Sly WS, ed. The Metabolic and Molecular Bases of Inherited Disease, vol 2. 8th e New York: McGraw- Hill; 2001:2835-2862.
  7. Mahley RW, Ji Z-S: Remnant lipoprotein metabolism. Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein J Lipid Res 1999; 40:1-16.
  8. Mahley Biochemistry and physiology of lipid and lipoprotein metabolism. In Becker KL [ed]. Principles and Practice of Endocrinology and Metabolism, Philadelphia. JB Lippincott 1995:1369-1378.
  9. Havel RJ, Kane JP: Introductio Structure and metabolism of plasma lipoproteins. In: Scriver CR, Beaudet AL, Sly WS, ed. The Metabolic and Molecular Bases of Inherited Disease, vol 2. 8th ed. New York: McGraw - Hill; 2001:2705-2716.
  10. Tsai L-Y, Tsai S-M, Lee S-C, Liu S-F: Falsely low LDL-cholesterol concentrations and artifactual undetectable HDL-cholesterol measured by direct methods in a patient with monoclonal parapro Clin Chim Acta 2005; 358:192-195.
  11. Disorders of lipoprotein metabolism. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Eds. Harrison’s Principles Of Internal Medicine: New York, Mcgraw Hill.
  12. Sumesh Raj, Rajasekharan C, Jayakumar B. Postprandial hypertriglyceridemia in type 2 diabetic subjec IJDDC 2006; 26 : 160-162
  13. Madhu SV, Mittal V, Krishna Ram B, Srivastava DK. Postprandial lipid abnormalities in type 2 diabetes mellitus 2005; 53: 1043-1046
  14. Howard BV, Robbins DC, Sievers ML, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2000; 20:830-8
  15. Lund S, Petersen M. ; Frandsen M. Sustained postprandial decrease in plasma levels of LDL cholesterol in patients with type-2 diabetes mellitus. Scand J clin lab invest 2008; 68(7) : 628-638.
  16. Rivellese AA, De Natale C, Di Marino L et a Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. J Clin Endocrinol Metab 2004; 89(5): 2153-9.

Corresponding Author

S.Pravin